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ABSTRACT 
This contribution investigates the interaction of two types of biomimetic-apatite colloidal nanoparti­
cles (negatively-charged 47 nm, and positively-charged 190nm NPs) with blood components, namely 
red blood cells (RBC) and plasma proteins, with the view to inspect their hemocompatibility. The NPs, 
preliminarily characterized by XRD, FTIR and DLS, showed low hemolysis ratio (typically lower than 
5%) illustrating the high compatibility of such NPs with respect to RBC, even at high concentration (up 
to 10 mg/ml). The presence of glucose as water-soluble matrix for freeze-dried and re-dispersed col­
loids led to slightly increased hemolysis as compared to glucose-free formulations. NPs{plasma protein 
interaction was then followed, via non-specific protein fluorescence quenching assays, by contact with 
whole human blood plasma. The amount of plasma proteins in interaction with the NPs was evaluated 
experimentally, and the data were fitted with the Hill plot and Stern-Volmer models. In ail cases, bind­
ing constants of the order of 101 -102 were found. These values, significantly lower than those reported 
for other types of nanoparticles or molecular interactions, illustrate the fairly inert character of these 
colloidal NPs with respect to plasma proteins, which is desirable for circulating injectable suspensions. 
Results were discussed in relation with particle surface charge and mean partide hydrodynamic diam­
eter (HD). On the basis of these hemocompatibility data, this study significantly complements previous 
results relative to the development and nontoxicity of biomimetic-apatite-based colloids stabilized by 
non-drug biocompatible organic molecules, intended for use in nanomedicine. 
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ose in nanomedicine. Whether surface-covered with heparin,
olyethyleneimine, or uncovered, a few previous literature works
tudied the blood compatibility of nanosized apatitic compositions
xhibiting different surface properties, or of apatite-coated mag-
etite NPs, in view of different kinds of applications such as drug
elivery [19,24,25] or for the fabricationof nano-contrast agents for
n vivo imaging [26]. In all cases, these apatitic or apatite-coated
Ps were not found to cause hemolysis (<5%) in the conditions
ested. Some other aspects also conveyed elements informing on
he high biocompatibility of apatitic or apatite-coated NPs, based
n the exploration of platelet activation [26], cytotoxicity [6,26,27],
n vivo acute toxicity [25], or else non pro-inﬂammatory potential
6]. Inspecting the behavior of (nano)particles with blood com-
onents also includes the study of their interaction with plasma
roteins. Montazeri et al. [28] showed that proteins could inter-
ct with ﬂuoride-substituted apatite powders, in a way dependent
n ﬂuoride content which may be optimized to improve biological
esponse. Lacerda et al. reported that gold NPs showed different
ypes of protein interaction according to their size and to the type
f proteins [17].
Taking into account the promise of apatite nanosystems in
edicine, the conﬁrmation of their high biocompatibility on an
xperimental basis therefore remains one key point, explaining the
ncreasing interest shownby the scientiﬁc/medical communities as
ighlighted above.
In particular, the interaction of dispersed apatite NPs with
lasma proteins has only seldom been explored, which is one
f the objectives of the present contribution. Also, apatite par-
icles easily agglomerate; consequently, formulations intended
or administrations through injections (whether intravenous or
ntratumoral for example) need be stabilized as colloidal-like
uspensions: this can be achieved through surface modiﬁcation
ia an organic corona. To be envisioned for use in the human
ody, this corona should also be composed of biocompatible con-
tituting molecules. In our approach initiated several years ago
1,22,29], this stabilization is for example realized by surface graft-
ng of either a phospholipid moiety (2-aminoethylphosphate, or
EP, representing hydrophilic head of the phospholipid phos-
hatidylethanolamine, a component of cell membranes) [30] or
phosphonate-terminated polyethyleneglycol (denoted (PEG)P).
btained stabilized apatite colloidal nanoparticles, involving a
iomimetic apatite phase close to bone mineral (nonstoichiomet-
ic apatite with surface active sites) [31] and stabilized with AEP,
ere for example shown to exhibit high cytocompatibility towards
ifferent types of cells (mesenchymal stem cells form adipose tis-
ue, breast cancer cells), and no pro-inﬂammatory potential was
etected when these NPs were contacted with human mono-
ytes/macrophages [6]. In thepresentwork, in addition to following
he interaction of human blood plasma proteins with both AEP-
nd (PEG)P-stabilized biomimetic apatite NPs, the contact with red
lood cells was also explored through hemolysis assays for com-
lementing their hemocompatibility evaluation.
. Materials and methods
.1. Synthesis of colloidal apatite NPs
Colloidal formulations were performed as described in a
revious work [21,22]. Brieﬂy, the precipitation of biomimetic
anocrystalline apatite was carried out in deionised water, at room
emperature and pH 9.5. After the mixing of a solution of calcium
itrate (1.15g in 18.75ml) and dispersing agent (AEP: 0.687g or
PEG)P: 0.396g) and a solution of di-ammonium hydrogen phos-
hate (0.21g in 6.25ml), the pH was adjusted to 9.5, by addition
f ammonia. The suspension was then placed in an oven preset at100 ◦C in a sealed vial for maturation of 16h. In this study, two
types of colloids, with different stabilizing agents, were investi-
gated: AEP, acting as an electrostatic stabilizing agent, and (PEG)P
acting by steric hindrance (MW: 5200g/mol). Both types of colloids
obtained were then puriﬁed by dialysis to remove unattached dis-
persing agent and any unreacted reagents, at room temperature,
with membranes of different Molecular Weight Cut-Off (MWCO),
respectively 6000–8000 and 12,000–14,000 MCWO for AEP and
(PEG)P colloids. The dialysis process, used to remove unreacted
species, is detailed elsewhere [32]. For AEP samples, an increase
of suspension viscosity may occur during dialysis. The addition of
sodium hexametaphosphate (denoted HMP) to this sample then
allowed obtaining well dispersed AEP-stabilized nanoparticles, as
well as a pH close to neutral. The ﬁnal pH of each colloid was
ﬁnally adjusted to the physiological value, which was undergone
on (PEG)P colloids by addition of HCl 0.37%. To study NPs inter-
actions with human blood components, some colloids were used
directly in the suspension state, and some others were lyophilized
and re-dispersed at the time of use. Prior to lyophilization, glucose
was added to each sample (0.066M) to keep colloidal properties
with unchanged particle HD after re-dispersion [23]. Each colloid
was then prepared to have a ﬁnal NaCl concentration of 0.9w/v%.
The notation “AN” and “AG” correspond to AEP-stabilized colloids
respectively in suspension (with NaCl) and in lyophilized form
(with glucose and NaCl). Similarly, for (PEG)-P-stabilized colloids,
the notations “PN” and “PG” will be used.
When mentioned in the text, a non-colloidal reference sample
was also prepared by following the same protocol as above but in
the absence of stabilizing agent.
2.2. Physico-chemical characterization of apatite colloidal NPs
The structure of the calcium phosphate nanoparticles con-
tained in freeze-dried suspensions was characterized by powder
X-ray diffraction using an Equinox 1000 curved-counter INEL
diffractometer (acquisition time 2h) with a cobalt anticathode
(Co =1.78892Å). Fourier transform infrared (FTIR) spectroscopy
analyses were performed on a Thermo-Nicolet 5700 spectrom-
eter with a resolution of 4 cm−1, in the wavenumber range of
400–4000 cm−1, using the KBr pellet method. Particle HD (deter-
mined by dynamic light scattering, DLS) was measured on a
NanosizerZSapparatus (Malvern Instruments,=630nm). Inorder
to evaluate surface charge of NPs, suspension or powder NPs were
diluted or dispersed in deionized water at an appropriate range
of concentration (1∼1.8mg/ml) and subjected to zeta potential
measurement utilizing Otsuka ELS-Z 1000 instrument. Zeta poten-
tial and hydrodynamic diameter of each apatite sample were also
evaluated after treatment in human plasma. Plasma obtained from
humanwholeblood (approvedby theYonseiUniversityWonjuCol-
lege of Medicine (Approval No. YWMR-12-6-030)) was diluted 50
timeswith Dulbecco’s phosphate buffered saline (DPBS) andmixed
with0.25mg/ml (for zetapotential) and1mg/ml (forDLS)of apatite
sample in 1:1 volume ratio.
2.3. Hemolysis assays
Hemolysis assay allowed evaluating the toxicity of our col-
loids on red blood cells (RBC) by following the possible release
of hemoglobin upon contact with the NPs. The procedure used
was inspired from other studies [33–35]. For these tests, whole
human blood samples were freshly obtained from a healthy vol-
unteer and directly used for the assay. These experiments utilizing
humanwholebloodwereapprovedby theYonseiUniversityWonju
College of Medicine (Approval No. YWMR-12-6-030). Deionized
water and saline were added to RBC suspension, as the positive
and negative controls, respectively.
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face calcium ions[29], as well as vibrational contributions in the
region 2900–3400 cm−1 related to the ammonium end-group in
AEP. In the case of (PEG)P, as can be expected from the long CH2-
CH2-O carbon chain, numerous additional bands become visible,First, colloidalNPswere suspended in saline in different concen-
rations, 1, 5 and 10mg/ml. Whole blood and colloid samples were
ixed in a 1:1 volume ratio, shaken with tapping, and then incu-
ated at 36.5 ◦C for 30min and 24h according to previous report
16,33]. After centrifugation at 3000 rpm for 5min, the supernatant
lasma was removed and let at room temperature during 30min
o allow oxyhemoglobin formation. The absorbance was then mea-
ured at 540nm with a UV/Vis spectrophotometer (SHIMADZU
V-1800). For the estimation of hemolysis percentage, the follow-
ng equation was used [36]:
emolysis% = (Sample absorbance − Negative control absorbance)
(Positive control absorbance − Negative control absorbance) × 100
(1)
Three apatite samples prepared on different days were sub-
ected to hemolysis assay to verify reproducibility. Each sample
as tested, and all nine test data were utilized to obtain average
nd standard deviation.
.4. Interaction with human plasma proteins—protein
uorescence quenching assay
It may be reminded that among most abundant plasma pro-
eins are human serum albumin (∼58%), immunoglobulin (∼38%)
nd ﬁbrinogen (∼4%). Experiments aiming at investigating inter-
ctions between colloidal apatite NPs and plasma proteins were
arried out in this work by using individual albumin, ﬁbrino-
en and immunoglobulin proteins as well as whole human blood
lasma. This study, approved by the Yonsei University Wonju Col-
ege of Medicine (Approval No. YWMR-12-6-030), was carried
ut by following the possible quenching of protein ﬂuorescence,
hich is attributed to the tryptophan residues in protein [37], upon
nteractionwith theNPsvia adsorption, agglomerationand/or com-
lexation [38].
Colloidsat concentrationsof0, 0.5, 1, 2, 4, 6, 8 and10mg/mlwere
dded to plasma (50 times diluted inDPBS) aliquots in a 1:1 volume
ixture, and put in a thermos-ﬁne-mixer (FINEPCR SH2000-DX) at
6.5 ◦C for 30min with gentle shaking. Luminescence spectropho-
ometry (Perkin-Elmer LS55, excitation wavelength 280nm, and
mission recorded at 340nm) was then used on suspension, to
etermine ﬂuorescence emission intensities. A protein ﬂuores-
ence quenching ratio was then quantiﬁed by the relation:
= (I0 − I)
I0
(2)
here I0 and I represent, respectively, ﬂuorescence intensities in
he absence and presence of colloids.
Three apatite samples prepared on different days were sub-
ected to ﬂuorescence quenching assay to verify reproducibility
f synthesis. Each sample was tested, and all nine test data were
tilized to obtain average and standard deviation.
. Results and discussion
.1. Physico-chemical characterization of apatite substrate
Figs. 1 and 2 show respectively the XRD and IR patterns of
on-colloidal (without dispersing agent) and colloidal particles sta-
ilized by AEP and (PEG)P.
XRD results (Fig. 1) conﬁrm the apatitic nature of the particles
s evidenced by comparison with JCPDS ﬁle #09-432 relative to
toichiometric hydroxyapatite. However, data analysis points out
lower degree of crystallinity for colloidal samples compared tohe non-colloidal reference. This lowered crystallinity has already
een discussed previously in the case of AEP-stabilized apatite col-
oids [29], and was explained by an inhibitory role of AEP blocking
ome growth surface sites on forming nanocrystals. In the case ofFig. 1. XRD patterns of biomimetic apatites: AEP- and (PEG)P-stabilized colloids, as
well as non-colloidal reference with main indexations after JCPDS ﬁle #09-432, and
pure (PEG)P.
(PEG)P-stabilized colloids, the crystallinity of the apatite phase is
less altered than in the case of AEP. This can be explained by the
larger size of the (PEG)Pmolecule, less prone to hinder apatite crys-
tal growth. TheXRDpattern relative to colloidalNPs in thepresence
of (PEG)P also showsadditional broaddiffraction lines (especially at
22.4 and27.3◦)which are characteristic of dried (PEG)P. As a control
experiment, we also validated by XRD (not shown here for the sake
of brevity) that pure (PEG)P did not undergo structural alterations
under the conditions used for the preparation of colloids (16h at
100 ◦C followed by freeze-drying).
FTIR spectral features (Fig. 2) conﬁrmed XRD conclusions,
evidencing vibrations bands characteristic of moderately-well
crystallized apatite; a lower resolution was observed for both
colloids as compared to the non-colloidal reference sample. The
presence of water bands was also revealed, which is customary
for biological or biomimetic apatites[39]. Moreover, the stretching
vibration mode of apatitic OH− ions, at 3572 cm−1 for hydroxya-
patite, as well as the liberation band at 632 cm−1, become less
pronounced for the colloids than for the non-colloidal reference,
indicating anonstoichiometryof the apatite phase inpresence, as in
bone apatite. Additional bands were however also observed in the
case of the colloidal NPs, and can be related to the presence of the
stabilizing agent. AEP-based apatite colloids displayed in particu-
lar a band at 754 cm−1, as previously reported, which is assignable
to the P-O-(C) group of AEP molecules in close contact with sur-Fig. 2. FTIR spectrum for AEP- and (PEG)P-stabilized colloids, as well as non-
colloidal reference and pure (PEG)P.
Fig. 3. Particle HD distributions of AEP and (PEG)P colloids as drawn from dynamic
light scattering (DLS).
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tround 2885 cm−1 attributable to C-H bonds, and in the region
90–1530 cm−1 where multiple contributions arise (C-H, C-C, C-
and P-O), which can be more clearly visualized on the spectrum
f pure (PEG)P (Fig. 2). From a chemical viewpoint, the AEP/apatite
olar ratio in the nanoparticles of AEP-stabilized colloids is close
o 0.7 as estimated from CHN elemental analyses, and the ratio
PEG)P/apatite is estimated to 0.17.
DLS analyses were then carried out to evaluate the particle HD
istribution of the colloidal particles obtained. As shown on Fig. 3,
he colloid stabilized with AEP was found to be composed of par-
icles exhibiting a monomodal distribution (polydispersity index
f 0.163) with a mean HD around 47nm. This was observed for
oth the AN and AG variants of this colloid. In contrast, the (PEG)P-
tabilized colloids PN and PGwere characterized byNPswithmean
Ds shifted to larger values, centered around 190 (polydispersity
ndex of 0.151). These results are in good agreement with XRD
esults which show larger crystal domain size for PN than for AN
olloids.
For both colloidal NPs types, zeta potential was also measured,
nd obtained values are summarized in Table 1. Non-colloidal non-
toichiometric apatite was reported to have a zeta potential value
lose to −10mV [29]. As can be seen from this table, there is a
igniﬁcant difference of particles charge between AEP and (PEG)P
amples. The smallest nanoparticles arenegatively charged, around
48mV, explained by the addition of a very negative group, HMP.
his colloids presents a very electronegative global surface charge,
ompared to (PEG)P colloids, which zeta potential is close to neu-
rality (slightly positive).able 1
eta potential measurements of apatite samples in deionized water and in the pres-
nce of plasma: colloidal samples stabilized with AEP (noted A) or with (PEG)P
noted P), either in liquid form (with NaCl, noted N), or freeze-dried (noted G) in
he presence of glucose and re-dispersed with NaCl.
Sample ID Samples only With plasma
pH Average zeta
potential (mV)
pH Average zeta
potential (mV)
AN 6.91 −40±5 7.41 −22±5
AG 7.02 −56±5 7.45 −17±5
PN 7.07 +6±5 7.43 −4.2±5
PG 7.05 +3.5±5 7.35 −6.3±53.2. Interaction between Red Blood Cells and
nanoparticles—hemolysis evaluation
The investigationof biomimetic colloidal apatiteNPs interaction
with RBC was carried out here by following the level of hemol-
ysis reached after 30min or 24h of contact (see experimental
section). Results concerning this hemolytic effect, depending on
colloid types and concentrations, are presented in Fig. 4. In the
literature, it is customary to consider the value of 5% hemolysis
as permissible for biomaterials applications (e.g. Refs. [40–42]).
It is apparent from this ﬁgure that none of the samples results
in serious hemolysis. The level of 5% hemolysis is never reached,
except for one type of colloid (AG) and at a very high initial con-
centration of 10mg/ml, which is beyond practical value. All other
hemolysis rates remain low, although increasing slightly with con-
centration and time. For AEP-based colloidal suspension AN (not
pre-lyophilized), RBC viability is even detected to be (in a repro-
ducible manner) better than for the negative control. This can be
explained either by the fact that even during in vitro incubation
for negative control, a limited number of cells may however get
denatured, and/or by a possible protective effect of this type of
colloid. Although AEP liquid (AN) and pre-lyophilized (AG) sam-
ples have quite similar physico-chemical properties (HD and zeta
potential), they present quite distinct hemolysis rates: AG col-
loids show somewhat larger RBC degradation, and the difference
is accentuated after 24h. The only differences between these two
variants of AEP-stabilized colloid are the presence of glucose for
facilitating the freeze-drying/redispersion process and a slightly
more negative zeta potential. Several reports have studied the
impact of glucose on human RBC membrane, which might indeed
explain our present results pointing to a slightly increased degree
of hemolysis on glucose-containing formulations: Quan et al. [43]
highlighted the cryopreservative effect of somesugar onRBCbefore
freeze-drying, but also some noxious effect. They showed that glu-
cose could induce an elevation of the inner osmorality of RBC
leading to osmotic fragility. Schiar et al. [44] also indicated that
glucose could increase, although in a limited extent, the toxicity of
organic and inorganic compoundsand raisehemolysis bymaintain-
ing reduced glutathione (GSH) level in erythrocytes. Viskupicova
et al. [45] emphasized the role of glucose incubation and concentra-
tion dependences on hemolysis; degradative processes increasing
with incubation time in the presence of glucose. However, even in
the presence of glucose in the AG and PG formulations, no serious
hemolysis ratewas reached in any case, unless veryhigh concentra-
tions were selected (typically larger than 10mg/ml) which would
be beyond usual practical usage. Considering that hemolysis of NPs
are generally carried out in the NP concentration between 0.01 and
2mg/ml [33,34], the slight toxic effect at 10mg/ml with current NP
is not serious.
Several studies showed that particles surface properties (and
in particular surface charge) could affect RBC degradation through
direct interaction with erythrocyte membranes. Han et al. [19]
studied the interaction between heparin-coated hydroxyapatite
nanoparticles and RBC. They demonstrated that their nanoparti-
cles had a strong tendency to favor RBC aggregation, compared
to micron-sized particles. They also explained that surface mod-
iﬁcation of these NPs (initially positively charged) with negative
charge through surface immobilization of the drug heparin, could
help to limit this cellular aggregation phenomenon, and therefore
decrease hemolysis. They concluded that hemocompatibility was
rather dependent on particle properties, and especially on surface
charge rather than particle size. If we exclude results on the freeze-
dried (and re-dispersed) colloids AG and PG, our hemolysis results
on AN and PN go also agree with these observations. In the case
of the AG and PG formulations, as stated above, the presence of
glucose is considered to explain the observed results.
F concentrations: 1, 5 and 10mg/ml, then mixed in a 1:1 volume ratio with blood), after
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Table 2
Analysis of protein ﬂuorescence quenching data: ﬁtted protein-NPs interaction
parameters using Hill and Stern-Volmer models.
Hill equation ﬁtted parameters
AN AG PN PG
n 0.923 1.17 0.75 0.74
kD 0.022 0.050 0.0084 0.012
Kb 45.14 19.86 119.5 82.09
r2 0.970 0.972 0.980 0.992
Stern-Volmer equation ﬁtted parameters
AN AG PN PGig. 4. Hemolytic effect of colloids at 3 different concentrations (initial suspension
0min and 24h of incubation.
Globally, this hemolysis study therefore points to a very high
emocompatibility of biomimetic apatite colloidal nanoparticles
tabilized by either AEP or (PEG)P as far as the interactions of NPs
ith RBC go. The next section will then examine the interaction
etween these NPs with whole human plasma containing in par-
icular another category of blood component: plasmatic proteins.
.3. Interaction between plasma proteins and
anoparticles—non-speciﬁc protein ﬂuorescence quenching study
The level of interaction between plasma proteins and our
olloidal NPs is another important aspect to consider for inspect-
ng hemocompatibility [38]. For example, the elimination of
athogens from the body will result in part by the activation of
he complement system (a group of plasma proteins active in the
mmunological body response); and bioavailability of the particles
ill be altered and probably decreased owing to phagocytosis. It is
hus interesting to check if NPs intended for use in contact with
lood may or not lead to an important interaction with plasma
roteins.
Protein binding was evaluated here, as was done previously
16], by following the degree of ﬂuorescence (through amino acid
esidues such as tyrosine and tryptophan) of plasma proteins
emaining in supernatants after contact with the NPs: a lumines-
ence quenching phenomenon is expected to occur in the case of
roteins adsorption on the particles.
Fig. 5 represents the obtained ﬂuorescence quenching ratio as
function of colloids concentrations, both in the case of indi-
idual proteins (Fig. 5a) and for while plasma (Fig. 5b). Overall,
he tendencies obtained for each triplicate system were found
o be very reproducible. All colloids show similar general trends,
ith increased ﬂuorescence quenching versus NPs concentrations.
esults do not change signiﬁcantly whether individual proteins
ere considered orwhile plasma. The AN, PN and PG colloids led to
ery similar results (up to 0.5–0.7 of quenching ratio), while the AG
ample showed even lower quenching effect (∼0.3 at 10mg/ml).
t may be remarked for example that these quenching ratios are
ound to be lower than previously reported values obtained on
raphite oxide nanoparticles [16]. In order to inspect more clearly
he level of interaction between NPs and plasma proteins, a ﬁtting
f the experimental data was then undergone, selecting the date
or whole plasma.
Two models were used and compared to analyze the protein
inding behavior of our NPs. First Hill equation (also correspond-
ng to Sips or Langmuir-Freundlich isotherm models) was used toksv 21.01 46.52 99.74 71.15
r2 0.981 0.991 0.993 0.984
describe the ﬂuorescence quenching data, as was done previously
on other systems [17]:
Q
Q max
= [NP]
n
knD + [NP]
n Hill equation (3)
where [NP] denotes the concentration of administeredNPs, Q is the
quenching ratio at concentration [NP],Qmax is themaximalquench-
ing ratio of 1, “n” is Hill parameter showing progressive protein
binding type on NPs, and kD is the protein-NP equilibrium con-
stant (at the experimental temperature of 36.5 ◦C). Hill equation
describes here protein-nanoparticles interaction in terms of bind-
ing and dissociation. Application of this equation can lead to two
major outcomes: Hill parameter “n” and the binding constant “Kb”.
Cases where n>1 correspond to adsorptive systems with a “pos-
itive cooperativity” among adsorbed proteins (proteins afﬁnity to
NPs progressively increases), while n<1 indicates that the binding
strength of the protein to the NP becomes progressively weaker as
further proteins adsorb. The particular case n=1 comes back to an
adsorption following a regular Langmuir model. Kb, the protein-NP
binding constant, is deﬁned by: Kb =1/kD.
The second model that was used here to analyze the protein
quenching results was Stern-Volmer equation [46]:
I0
I
= 1 + ksv · [NP]Stern-Volmer (4)
where [NP] is the concentrationofNPs, I0 the intensity or rate of ﬂu-
orescencewithout a quencher, I the intensity or rate of ﬂuorescence
with a quencher, and ksv the protein-NP equilibrium constant. This
model is generallymore suitable for low concentrations (a “domain
where quenching is dominated by diffusive transport” [17]); it
was considered here for [NP] up to 4mg/ml. The ﬁtted parame-
ters obtained when applying both models to our data are reported
on Table 2.
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tig. 5. Fluorescence quenching properties of (a) human serum proteins and full ser
In each case, correlation coefﬁcients r2 larger than 0.97 (for
ill plot r2 ≥0.970, for Stern-Volmer plot r2 > 0.98) were noticed
ndependently of the model (Hill or Stern-Volmer), pointing out
he pertinence of these ﬁts. The n parameters found with the Hill
quation are close to 1 or larger than 1, in the case of AEP col-
oids, suggesting cooperative adsorption of proteins. In contrast,
value of ∼0.75 was observed for (PEG)P. While AEP (and HMPounterions) are small organic molecules with low space occu-
ancy, thus provoking low steric hindrance to protein adsorption,
olyethyleneglycol molecules are voluminous; this difference in
he size of organic coronas between AEP- and (PEG)P-stabilized) summary of data for pure serum, after contact with (PEG)P and AEP colloids.
colloids could explain the difference in the observed proteins
adsorptive behaviors for the two types of colloids.
In terms of binding constants, both models lead to values with
an order of magnitude in the range 101–102 (between 19 and 120
for Hill Kb and between 20 and 100 for Stern-Volmer KSV ). Compar-
atively, signiﬁcantly larger values were reported in the literature
for several other types of nanoparticles (e.g. of the order 104–107for citrate-coated gold nanoparticles [17], of the order of 103 for
graphite oxide nanoparticles [16]). Also, values of the order of
104–105 were reported for the interaction of ﬂavonoids (a group of
polyphenols with potential biomedical applications) with bovine
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[erum albumin [46]. These ﬁndings suggest that the biomimetic
patite-based colloidal nanoparticles tested in this work are fairly
nert toward plasma proteins. These results appear all the more
ppealing that these colloidal biomimetic apatite nanoparticles are
airly inert to plasma proteins thanks to “passive” organic coronas
AEP phospholipid moiety or phosphonated polyethyleneglycol)
nd do not necessitate additional stabilization via adsorption of a
rug such as heparin [19].
Upon treating the samples with blood plasma, it may be noted
hat DLS measurements led to similar results (within less than 3.5%
f difference) before and after plasma contact. In contrast, zeta
otential values were signiﬁcantly modiﬁed: highly negative zeta
otential of AN and AG shifted to less negative region and posi-
ive apatites like PN and PG began to have slightly negative values
see Table 1). These results can be explained by partial protein
overage upon contact with plasma, proteins being known to
xhibit negatively-charged residues at physiological pH.
The above discussion thus pointed out the relative inertness
f the colloidal NPs tested here with plasma proteins in all cases,
hich is desirable for usage in nanomedicine. Among the four types
f colloids evaluated, some differences of adsorptive behavior can
owever be distinguished. For any given model, the same gen-
ral pattern AN<AG<PG<PN is found for interaction constants.
rotein-apatite interaction is bound to be greatly governed by NPs
haracteristics where several parameters may come into play such
s surface properties (surface charge, accessibility to surface sites
espite organic corona steric hindrance, molecular composition
f the corona, speciﬁc surface area. . .) and particle HD. If parti-
le HD was considered alone, AEP colloids (composed of NPs with
D∼47nm)would be expected to have a larger interaction surface
nd thus to lead to greater interaction with proteins than (PEG)P
olloids (NPs∼190nm), especially taking into account the larger
pace occupancy of polyethyleneglycol. However, this tendency
oes not ﬁt experimental results (Table 2), indicating that other
actors should also be considered, such as surface charge. Indeed,
EP-stabilized colloids are negatively-charged (by way of the HMP
reatment) which could explain their lower afﬁnity for proteins
which expose negative end-groups from amino acid residues)
ompared to the positively-charged (PEG)P-stabilized colloids (PN
nd PG).
.4. Concluding remarks
In this contribution, we followed the interaction of two types
f biomimetic-apatite colloidal nanoparticles with blood compo-
ents, namely red blood cells (via hemolysis assays) and plasma
roteins (follow-up of non-speciﬁc protein adsorption via protein
uorescence quenching).
Hemolysis degrees lower than 5% were observed, pointing out
he high hemocompatibility of such colloids with respect to red
lood cells. Only one condition (glucose-containing AEP-based
reeze-dried colloid) led to a larger level of hemolysis, but this
as noticed for high concentration (10mg/ml) which is beyond
xpected practical usage, and this result is likely related to the
resence of glucose in the formulation. For such colloids, additional
esearch is in progress to select even more suitable soluble matri-
es for the preparation and re-dispersion of freeze-dried apatite
olloids.
In a second stage, the interaction of the NPs with whole human
lood plasma as well as with individual proteins was investigated.
y following protein luminescence quenching in the presence of
he colloids, the extent of NPs/plasma proteins interaction was
valuated experimentally, and the data were then ﬁtted with two
odels, namely Hill and Stern-Volmer. In all cases and indepen-
ently of the selected model, interaction constants of the order of
01–102 were found. These values, signiﬁcantly lower than those
[reported for other types of nanoparticles ormolecular interactions,
indicate the fairly inert character of these colloidalNPswith respect
to plasma proteins, again stressing their high hemocompatibility.
It may be noted that, among the four types of colloids (intended
for a systemic administration pathway) tested in this study,
both hemolysis assays and protein ﬂuorescence quenching data
indicated that the AEP-stabilized colloid (not lyophilized) corre-
sponded to the most hemocompatible formulation. It is delicate
at this point to determine whether particle size or surface charge
is the most relevant factor to take into account in relation with
hemocompatibility of such systems. Indeed, both particle size and
zeta potential tend to vary simultaneously when changing AEP by
(PEG)P. However, it may be concluded from our observations that
apatite nanoparticles having initially negative to slightly positive
surface charge are compatible to blood components. Also, since the
surface charge appears to have eventually a tendency to become
slightly negative in all cases after plasma contact, probably due to
some extent of protein coverage (partial), then the surface charge
parameter is probably less relevant than particle size to distinguish
between different categories of apatite colloids, as size remains a
characteristic feature of the particles.
This study complements the existing research carried out on
biomimetic-apatite-based colloids stabilized by non-drug biocom-
patible organic molecules. It adds hemocompatibility evidences to
the already reported low cytotoxicity and non-pro-inﬂammatory
properties of AEP-stabilized apatite colloids. Future work will aim,
among other things, at exploring NPs/cells membranes interac-
tions, and following NPs biodistribution in vivo.
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